Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101569 · ClinicalTrials.gov registry record · Phase 3
Aripiprazole Oral Acceptability Trial
A Phase 3 study of Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
- 7
- Study locations
NCT00101569: Completed Phase 3 study of Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00101569 is a Phase 3 study of Schizophrenia that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 59 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00101569, a Phase 3 study of Schizophrenia, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
Conditions Studied
Interventions
- DRUG Aripiprazole
Study Locations (7)
California
- Local Institution - Anaheim
- Local Institution - National City
Florida
- Local Institution - North Miami Beach
Kansas
- Local Institution - Overland Park
New York
- Local Institution - Staten Island
Oklahoma
- Local Institution - Oklahoma City
Virginia
- Local Institution - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
What the finished NCT00101569 record still lists
NCT00101569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00101569 lists 7 locations in 6 states (California, Florida, Kansas).
Frequently Asked Questions
What is clinical trial NCT00101569 about?
NCT00101569 is a clinical study titled "Aripiprazole Oral Acceptability Trial". The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
What is the current status of trial NCT00101569?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2004-03. Estimated completion is 2005-03.
What conditions does trial NCT00101569 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00101569?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00101569?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00101569 being conducted?
This trial has 7 study locations across California, Florida, Kansas, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00101569's enrollment target sits among peer trials
59 198th of 315 higher than 117 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia